Helping patients with rare genetic disorders of obesity
 

The Genetic Obesity Project is dedicated to improving the understanding, diagnosis, and treatment of severe obesity that is caused by specific genetic defects–particularly rare genetic disorders that result in life-threatening obesity.

LEARN MORE >

Patient Stories
Single genetic defects along the MC4 pathway that result in early-onset and severe obesity are now identified.

PATIENT STORIES >

Healthcare Professionals and Patients & Caregivers:

Join the Project
The Genetic Obesity Project has launched the Genetic Obesity-ID (GO-ID) initiative focused on identifying people with POMC deficiency and LEPR deficiency obesity.

LEARN MORE & PARTICIPATE >

Interested in The Genetic Obesity Project? Stay informed about our latest developments and projects.

  • LATEST NEWS: 02/01/2017: Endocrine Society Issues Pediatric Obesity Clinical Practice Guideline LEARN MORE >     |   
This program is supported by Rhythm, a Boston-based biopharmaceutical company developing the MC4R peptide agonist, setmelanotide (RM-493), for obesity caused by genetic deficiencies in the MC4 pathway.
Back to Top